Filtered By:
Therapy: Endocrine Therapy
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 2859 results found since Jan 2013.
Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy
CONCLUSION: Factors related to tumor aggressiveness and treatment were associated with early recurrence, whereas patient related factors were related to late recurrence. These data may help guide treatment strategies and surveillance approaches for patients with ILC.PMID:37464134 | DOI:10.1245/s10434-023-13881-x
Source: Ann Oncol - July 18, 2023 Category: Cancer & Oncology Authors: Harriet T Rothschild Elle N Clelland Firdows Mujir Helena Record Jasmine Wong Laura J Esserman Michael Alvarado Cheryl Ewing Rita A Mukhtar Source Type: research
LncRNA AGPG confers endocrine resistance in breast cancer by promoting E2F1 activity
Cancer Res. 2023 Jul 18:CAN-23-0015. doi: 10.1158/0008-5472.CAN-23-0015. Online ahead of print.ABSTRACTResistance to endocrine therapy represents a major concern for patients with estrogen receptor α positive (ERα+) breast cancer. Endocrine therapy resistance is commonly mediated by activated E2F signaling. A better understanding of the mechanisms governing E2F1 activity in resistant cells could reveal strategies for overcoming resistance. Here, we identified the long non-coding RNA (lncRNA) actin gamma 1 pseudogene 25 (AGPG) as a regulator of E2F1 activity in endocrine resistant breast cancer. Expression of EGPG was inc...
Source: Cell Research - July 18, 2023 Category: Cytology Authors: Shiyi Yu Ying Wang Xue Gong Zhehao Fan Zheng Wang Zhengyan Liang Rui Wu Binjie Cao Ning Wang Caili Bi Dan Lv Haibo Sun Source Type: research
Advances in bio-immunotherapy for castration-resistant prostate cancer
J Cancer Res Clin Oncol. 2023 Jul 18. doi: 10.1007/s00432-023-05152-9. Online ahead of print.ABSTRACTProstate cancer is one of the significant diseases that threaten the survival of men worldwide, with the progression of androgen deprivation therapy, become much rely on it, finally, developed into castration-resistant prostate cancer (ADT). In western countries, ranks second in incidence, and in China, with increasing lifespan, the incidence of prostate cancer is rising steadily. Although chemotherapy agents, such as taxane, have achieved some efficacy, treatment failure still occur. As sensitivity of hormone levels change...
Source: Clinical Prostate Cancer - July 17, 2023 Category: Cancer & Oncology Authors: Canling Lin Yonghui Chen Liji Shi Huarong Lin Hongmei Xia Weihua Yin Source Type: research
Clinical Behavior, Management, and Treatment Response of Estrogen Receptor Low (1-10%) Breast Cancer
CONCLUSIONS: This study suggests that the tumor features and clinical management of ER-low tumors vary significantly by PR expression. Within ER-low tumors, PR- tumors more closely resemble ER- BC, while PR+ tumors exhibit less aggressive characteristics. In ER-low disease selected for treatment with NAC, response is similar to ER- regardless of PR status.PMID:37460743 | DOI:10.1245/s10434-023-13846-0
Source: Ann Oncol - July 17, 2023 Category: Cancer & Oncology Authors: Dan Moldoveanu Tanya L Hoskin Courtney N Day Amy K Schulze Matthew P Goetz Judy C Boughey Source Type: research
Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)
CONCLUSIONS: Probiotic Bifidobacterium or the combination of probiotic Bifidobacterium with TM did not decrease the incidence of grade 2 or greater diarrhea compared with historical control, although the grade 3 or greater diarrhea was reduced.CLINICAL TRIAL REGISTRATION: jRCT (Japan registry of clinical trials). jRCTs031190154.PMID:37459790 | DOI:10.1016/j.breast.2023.07.003
Source: Cancer Control - July 17, 2023 Category: Cancer & Oncology Authors: Hiroko Masuda Yuko Tanabe Hitomi Sakai Koji Matsumoto Akihiko Shimomura Mihoko Doi Yasuo Miyoshi Masato Takahashi Yasuaki Sagara Shinya Tokunaga Tsutomu Iwasa Naoki Niikura Kenichi Yoshimura Toshimi Takano Junji Tsurutani Source Type: research
Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ER α < sup > + < /sup > breast cancer
EMBO Mol Med. 2023 Jul 17:e17248. doi: 10.15252/emmm.202217248. Online ahead of print.ABSTRACTEndocrine therapies targeting estrogen signaling, such as tamoxifen, have significantly improved management of estrogen receptor alpha (ERα)-positive breast cancers. However, their efficacy is limited by intrinsic and acquired resistance to treatment, and there is currently no predictive marker of response to these anti-estrogens to guide treatment decision. Here, using two independent cohorts of breast cancer patients, we identified nuclear PRMT5 expression as an independent predictive marker of sensitivity to tamoxifen. Mechani...
Source: Molecular Medicine - July 17, 2023 Category: Molecular Biology Authors: Coralie Poulard Thuy Ha Pham Youenn Drouet Julien Jacquemetton Ausra Surmielova Loay Kassem Benoite Mery Christine Lasset Jonathan Reboulet Isabelle Treilleux Elisabetta Marangoni Olivier Tr édan Muriel Le Romancer Source Type: research
Advances in bio-immunotherapy for castration-resistant prostate cancer
J Cancer Res Clin Oncol. 2023 Jul 18. doi: 10.1007/s00432-023-05152-9. Online ahead of print.ABSTRACTProstate cancer is one of the significant diseases that threaten the survival of men worldwide, with the progression of androgen deprivation therapy, become much rely on it, finally, developed into castration-resistant prostate cancer (ADT). In western countries, ranks second in incidence, and in China, with increasing lifespan, the incidence of prostate cancer is rising steadily. Although chemotherapy agents, such as taxane, have achieved some efficacy, treatment failure still occur. As sensitivity of hormone levels change...
Source: Clinical Prostate Cancer - July 17, 2023 Category: Cancer & Oncology Authors: Canling Lin Yonghui Chen Liji Shi Huarong Lin Hongmei Xia Weihua Yin Source Type: research
Clinical Behavior, Management, and Treatment Response of Estrogen Receptor Low (1-10%) Breast Cancer
CONCLUSIONS: This study suggests that the tumor features and clinical management of ER-low tumors vary significantly by PR expression. Within ER-low tumors, PR- tumors more closely resemble ER- BC, while PR+ tumors exhibit less aggressive characteristics. In ER-low disease selected for treatment with NAC, response is similar to ER- regardless of PR status.PMID:37460743 | DOI:10.1245/s10434-023-13846-0
Source: Ann Oncol - July 17, 2023 Category: Cancer & Oncology Authors: Dan Moldoveanu Tanya L Hoskin Courtney N Day Amy K Schulze Matthew P Goetz Judy C Boughey Source Type: research
Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)
CONCLUSIONS: Probiotic Bifidobacterium or the combination of probiotic Bifidobacterium with TM did not decrease the incidence of grade 2 or greater diarrhea compared with historical control, although the grade 3 or greater diarrhea was reduced.CLINICAL TRIAL REGISTRATION: jRCT (Japan registry of clinical trials). jRCTs031190154.PMID:37459790 | DOI:10.1016/j.breast.2023.07.003
Source: Breast - July 17, 2023 Category: Cancer & Oncology Authors: Hiroko Masuda Yuko Tanabe Hitomi Sakai Koji Matsumoto Akihiko Shimomura Mihoko Doi Yasuo Miyoshi Masato Takahashi Yasuaki Sagara Shinya Tokunaga Tsutomu Iwasa Naoki Niikura Kenichi Yoshimura Toshimi Takano Junji Tsurutani Source Type: research
Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen in ER α < sup > + < /sup > breast cancer
EMBO Mol Med. 2023 Jul 17:e17248. doi: 10.15252/emmm.202217248. Online ahead of print.ABSTRACTEndocrine therapies targeting estrogen signaling, such as tamoxifen, have significantly improved management of estrogen receptor alpha (ERα)-positive breast cancers. However, their efficacy is limited by intrinsic and acquired resistance to treatment, and there is currently no predictive marker of response to these anti-estrogens to guide treatment decision. Here, using two independent cohorts of breast cancer patients, we identified nuclear PRMT5 expression as an independent predictive marker of sensitivity to tamoxifen. Mechani...
Source: Molecular Medicine - July 17, 2023 Category: Molecular Biology Authors: Coralie Poulard Thuy Ha Pham Youenn Drouet Julien Jacquemetton Ausra Surmielova Loay Kassem Benoite Mery Christine Lasset Jonathan Reboulet Isabelle Treilleux Elisabetta Marangoni Olivier Tr édan Muriel Le Romancer Source Type: research
The POWER-PAK Score Characterizes Tumor Response to 3 Months of Preoperative Endocrine Therapy
CONCLUSIONS: The tumor responses following treatment with pre-ET are heterogenous. We propose that the POWER-PAK scoring system can be used to quantify response to pre-ET. Future studies will explore the use of POWER-PAK to support informed decision-making for adjuvant therapy options for older women with early stage breast cancer.PMID:37454014 | DOI:10.1245/s10434-023-13892-8
Source: Ann Oncol - July 15, 2023 Category: Cancer & Oncology Authors: Max O Meneveau Michael P Crawford Lena M Turkheimer Trish A Millard Kristen A Atkins Shayna L Showalter Source Type: research
